The week of June 3 in review, featuring content on crizotinib in NSCLC, an FDA approval, novel agents for the treatment of prostate cancer, and more.
Crizotinib demonstrated superiority to chemotherapy for the treatment of previously treated, advanced non-small cell lung cancer (NSCLC) with ALK rearrangement in a trial published online by The New England Journal of Medicine on June 1.
Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, gives an overview of the treatment of advanced melanoma at the 2013 ASCO Annual Meeting.
The immunomodulatory agent lenalidomide (Revlimid) has been approved by the FDA to treat patients with mantle cell lymphoma (MCL) who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, comments on the impact of the approval of radium-223 for bone metastases from prostate cancer.
In the wake of the approval of several novel treatments for prostate cancerincluding antiandrogens enzalutamide and abiraterone and immunotherapy sipuleucel-T, physicians must now focus on how best to integrate new therapies into the treatment of patients with prostate cancer.
The new “in” term among those looking to lower the cost of healthcare is “bundled payment” (BP). Although there is still disagreement about what it means, the bundling of payments revolves around oncologists being paid a set fee for managing their patients’ care.
Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, describes the use of vinegar (acetic acid) as a cervical cancer screening tool.